178 related articles for article (PubMed ID: 22127489)
1. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels.
Shimazu S; Shimatsu A; Yamada S; Inoshita N; Nagamura Y; Usui T; Tsukada T
Eur J Endocrinol; 2012 Mar; 166(3):383-90. PubMed ID: 22127489
[TBL] [Abstract][Full Text] [Related]
2. Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.
Bueno C; Trarbach EB; Bronstein MD; Glezer A
Pituitary; 2017 Jun; 20(3):295-300. PubMed ID: 27848079
[TBL] [Abstract][Full Text] [Related]
3. Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?
Ilhan M; Kahraman OT; Turan S; Turgut S; Karaman O; Zeybek U; Shukurov S; Yaylim I; Tasan E
Ann Endocrinol (Paris); 2015 Oct; 76(5):614-9. PubMed ID: 26514951
[TBL] [Abstract][Full Text] [Related]
4. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.
Filopanti M; Lania AG; Spada A
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):43-53. PubMed ID: 19929252
[TBL] [Abstract][Full Text] [Related]
6. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
[TBL] [Abstract][Full Text] [Related]
7. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
Caccavelli L; Morange-Ramos I; Kordon C; Jaquet P; Enjalbert A
J Neuroendocrinol; 1996 Oct; 8(10):737-46. PubMed ID: 8910802
[TBL] [Abstract][Full Text] [Related]
8. Either isoform of the dopamine D2 receptor can mediate dopaminergic repression of the rat prolactin promoter.
McChesney R; Sealfon SC; Tsutsumi M; Dong KW; Roberts JL; Bancroft C
Mol Cell Endocrinol; 1991 Aug; 79(1-3):R1-7. PubMed ID: 1834494
[TBL] [Abstract][Full Text] [Related]
9. [Development of secondary resistance to dopamine agonists in a patient with giant prolactinoma].
Astaf'eva LI; Kadashev BA; Trunin IuIu; Rotin DL
Zh Vopr Neirokhir Im N N Burdenko; 2010; (4):48-51; discussion 51-2. PubMed ID: 21374937
[TBL] [Abstract][Full Text] [Related]
10. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
11. The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas.
Athanasoulia AP; Sievers C; Uhr M; Ising M; Stalla GK; Schneider HJ
Pituitary; 2014 Jun; 17(3):240-5. PubMed ID: 23740147
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.
Filopanti M; Barbieri AM; Angioni AR; Colao A; Gasco V; Grottoli S; Peri A; Baglioni S; Fustini MF; Pigliaru F; Monte PD; Borretta G; Ambrosi B; Jaffrain-Rea ML; Gasperi M; Brogioni S; Cannavò S; Mantovani G; Beck-Peccoz P; Lania A; Spada A
Pharmacogenomics J; 2008 Oct; 8(5):357-63. PubMed ID: 18332900
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic resistance in prolactinoma patients.
Molitch ME
Pituitary; 2005; 8(1):43-52. PubMed ID: 16411068
[TBL] [Abstract][Full Text] [Related]
14. Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression.
Pellegrini-Bouiller I; Morange-Ramos I; Barlier A; Gunz G; Figarella-Branger D; Cortet-Rudelli C; Grisoli F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1996 Sep; 81(9):3390-6. PubMed ID: 8784102
[TBL] [Abstract][Full Text] [Related]
15. Retention of dopamine 2 receptor mRNA and absence of the protein in craniospinal and extracranial metastasis of a malignant prolactinoma: a case report.
Winkelmann J; Pagotto U; Theodoropoulou M; Tatsch K; Saeger W; Müller A; Arzberger T; Schaaf L; Schumann EM; Trenkwalder C; Stalla GK
Eur J Endocrinol; 2002 Jan; 146(1):81-8. PubMed ID: 11751072
[TBL] [Abstract][Full Text] [Related]
16. Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-kappaB.
Fiorentini C; Guerra N; Facchetti M; Finardi A; Tiberio L; Schiaffonati L; Spano P; Missale C
Mol Endocrinol; 2002 Feb; 16(2):353-66. PubMed ID: 11818506
[TBL] [Abstract][Full Text] [Related]
17. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
18. Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism.
Missale C; Losa M; Sigala S; Balsari A; Giovanelli M; Spano PF
Mol Endocrinol; 1996 Mar; 10(3):272-85. PubMed ID: 8833656
[TBL] [Abstract][Full Text] [Related]
19. Tumor stem-like cells isolated from MMQ cells resist to dopamine agonist treatment.
Cai L; Chen J; Lu J; Li Q; Chen X; Zhang L; Wu J; Zheng W; Wang C; Su Z
Mol Cell Endocrinol; 2021 Sep; 535():111396. PubMed ID: 34271069
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.
Caccavelli L; Feron F; Morange I; Rouer E; Benarous R; Dewailly D; Jaquet P; Kordon C; Enjalbert A
Neuroendocrinology; 1994 Sep; 60(3):314-22. PubMed ID: 7969790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
